Literature DB >> 7006062

Cell-mediated immunity against Francisella tularensis after natural infection.

P Koskela, E Herva.   

Abstract

31 subjects with tularemia recently or up to 11 years earlier were studied for cell-mediated immunity against Francisella tularensis using formalin-killed bacteria as antigen in the lymphocyte blast transformation test. Lymphocytes from all the subjects responded to F. tularensis antigen both in separated mononuclear cell and whole blood cultures, whereas lymphocytes from 12 controls responded not at all or only weakly to hig antigen concentrations and only in separated mononuclear cell cultures. The strength of the response remained on the same level as in the cases of recent infection up to 11 years. There was no correlation between the lymphocyte responses and the serum antibodies agglutinating F.l tularensis antigen. Purified protein derivative of tuberculin equally stimulated the cells from the tularemia and control subjects. The lymphocyte stimulation methods can bae used to diagnose infections caused by F. tularensis and to measure cell-mediated immunity and resistance against such infections.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7006062     DOI: 10.3109/inf.1980.12.issue-4.08

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  16 in total

Review 1.  Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.

Authors:  A Tärnvik; M Eriksson; G Sandström; A Sjöstedt
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

2.  Kinetics of the immune response associated with tularemia: comparison of an enzyme-linked immunosorbent assay, a tube agglutination test, and a novel whole-blood lymphocyte stimulation test.

Authors:  Henrik Eliasson; Per Olcén; Anders Sjöstedt; Margareta Jurstrand; Erik Bäck; Sören Andersson
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

3.  Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans.

Authors:  H M El Sahly; R L Atmar; S M Patel; J M Wells; T Cate; M Ho; K Guo; M F Pasetti; D E Lewis; M B Sztein; W A Keitel
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

4.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

5.  Interleukin 2 and gamma interferon production, interleukin 2 receptor expression, and DNA synthesis induced by tularemia antigen in vitro after natural infection or vaccination.

Authors:  R Karttunen; G Andersson; H P Ekre; K Juutinen; H M Surcel; H Syrjälä; E Herva
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

6.  Interleukin 2 production in whole blood culture: a rapid test of immunity to Francisella tularensis.

Authors:  R Karttunen; J Ilonen; E Herva
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

7.  Humoral immunity against Francisella tularensis after natural infection.

Authors:  P Koskela; A Salminen
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

8.  Various membrane proteins of Francisella tularensis induce interferon-gamma production in both CD4+ and CD8+ T cells of primed humans.

Authors:  A Sjöstedt; M Eriksson; G Sandström; A Tärnvik
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 9.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

10.  Cell-mediated and humoral immunity induced by a live Francisella tularensis vaccine.

Authors:  P Koskela; E Herva
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.